Recommendation | The Strongest New Drug Pipeline for 2026: 15 Potential Blockbusters on the Horizon

Revolution Medicines’ Rasonque (daraxonrasib) received FDA approval on August 26, 2026. This once-daily oral, broad-spectrum RAS(ON) multi-selective inhibitor employs a unique chemical mechanism that recruits cyclophilin A to form a ternary complex with activated RAS, thereby blocking its downstream signaling. In the Phase III RASolute 302 trial, median overall survival in patients with metastatic pancreatic cancer improved from 6.7 months with chemotherapy to 13.2 months with Rasonque—a 60% reduction in risk of death; progression-free survival nearly doubled as well. The FDA label does not require patient selection based on specific RAS mutations and permits use in metastatic patients unsuitable for multi-drug systemic therapy, preserving a treatment option for certain first-line patients. Rasonque’s wholesale acquisition cost is $39,800 per 30-day supply. Ongoing development includes expansion into first-line metastatic pancreatic cancer, adjuvant therapy, and non-small cell lung cancer. RBC estimates peak global sales potential at approximately $11.5 billion, while Evaluate projects cross-indication peak sales as high as $21 billion. Its industry significance extends beyond pancreatic cancer: while KRAS G12C inhibitors proved RAS is druggable, Rasonque aims to demonstrate that RAS-targeted therapies can become a broad, commercially scalable market. 3. Foundayo: Oral Small-Molecule GLP-1 Agonist with >$10 Billion Commercial Potential Eli Lilly’s Foundayo (orforglipron) received FDA approval in April 2026. Unlike peptide-based GLP-1 drugs such as semaglutide, Foundayo is a chemically synthesized, non-peptide, small-molecule GLP-1 receptor agonist administered orally once daily—without dietary or fluid restrictions. Foundayo’s differentiation lies not in setting new weight-loss records but in transforming GLP-1 therapy into a conventional chronic-disease treatment paradigm. As a small molecule, it bypasses manufacturing, fill-finish, and certain supply-chain bottlenecks inherent to peptide injectables. Given that the global population of people with obesity vastly exceeds current GLP-1-treated patients, a convenient, orally administered tablet offers significant potential to expand access to primary care settings, earlier intervention, and patients averse to long-term injections. Evaluate projected 2032 sales at approximately $11.8 billion. Retatrutide increases…

Up to $2.3 Billion Licensing Deal Sends Hanmi Pharma Stock Up 30%: The Weight-Loss Drug War Enters the 'Body Composition Era'

Lean mass is not identical to skeletal muscle. DXA-measured lean mass includes water, organs, and other non-muscle components; thus, directly translating 'lean mass loss' as 'how much muscle was lost' is imprecise. However, when weight loss reaches 15%, 20%, or higher, preservation of muscle mass, strength, and physical function becomes increasingly critical—especially for older adults, individuals at risk of sarcopenia, and those requiring long-term treatment. Accordingly, the key performance indicators (KPIs) for weight-loss drugs are shifting. Previously, the central question was: How many kilograms can it shed? Now, the focus has evolved to: What, exactly, is being lost? This shift is profoundly important. The weight-loss drug war has already progressed through four rounds: Round One was straightforward: Who achieves greater weight loss? Wegovy ushered in the ~15% weight-loss era; Zepbound pushed the ceiling even higher. Eli Lilly’s retatrutide, now in Phase III, reported in an 80-week study that the highest dose achieved a mean weight loss of 22.6%; Lilly plans to submit its FDA application in Q1 2027. (Reuters) As pharmacologic weight loss approaches bariatric surgery efficacy, gaining an additional two or three percentage points remains valuable—but is no longer the sole battleground. Round Two: Who offers greater convenience? 2026 marks the true commercial launch of oral weight-loss drugs. Novo Nordisk’s oral Wegovy formulation has entered the U.S. market, and Eli Lilly’s small-molecule oral GLP-1 agonist orforglipron (brand name Foundayo) received FDA approval on April 1, 2026. Eliminating the need for peptide injections significantly impacts production costs, supply capacity, and patient acceptance. (U.S. Food and Drug Administration) Novo Nordisk even launched a new late-stage clinical trial this month to assess whether a lower maintenance dose of oral Wegovy remains effective—indicating that questions now extend beyond efficacy alone to include cost, side effects, and long-term adherence. (Reuters) Round Three: Who improves patient comfort? Nausea, vomiting, and diarrhea—gastrointestinal adverse events—are persistent, unavoidable realities with incretin-based therapies. Hence, Amylin suddenly…

Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs

Sep 14, 2026

Eli Lilly announced its oral obesity drug Foundayo captured over 30% of new US patients, narrowing the gap with rival Novo Nordisk. Market analysts expect the obesity treatment sector to reach over $100 billion annually in the U.S. by 2030.

reuters

2026-01-13

Jan. 13 Business Watch: Plants Close in Brazil and the UK; Lilly to Pay $1.2 Billion for Ventyx

2026-04-17

Lilly's obesity pill Foundayo gets 1,390 prescriptions in debut week

2026-04-19

Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

2026-04-24

Eli Lilly's Obesity Pill Records Modest Second Week as Battle with Novo Nordisk Intensifies

2026-04-30

S&P 500, Nasdaq On Course for Best Month Since 2020 Despite Middle East Risks